All In Biotech

Drug Trial Radar · NCT07512583

Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors

Phase Ib/II Clinical Trial of TQB2930 Injection in Combination With TQB2102 for Injection in Patients With HER2-Expressing Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

178

Planned (sponsor's estimate)

Start

May 27, 2026

Primary completion

Mar 2028

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Apr 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, multi-cohort phase Ib/II clinical study to evaluate the efficacy and safety of TQB2930 in combination with TQB2102 in patients with HER2-expressing advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • TQB2930 injection+TQB2102 for injectionDrug

    TQB2930 Injection is a Human Epidermal Growth Factor Receptor 2 (HER2) bispecific antibody. TQB2102 for injection is a HER2 - targeted dual epitope Antibody-Drug Conjugate (ADC).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase 2 DoseTime frame: From first dose to 21days after first dose
  2. Overall response rate (ORR)Time frame: The estimated duration was 23 months from enrollment of the first patient to 6 months after enrollment of the last patient

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute&Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.